As others have reported, the India Intellectual Property Appeals Board (IPAB) has upheld the compulsory license on the Bayer patents on the cancer drug sorafenib, sold under the trademark of Nexavar by Bayer.
KEI comment on the Medicines Patent Pool license and MoU with ViiV Healthcare
28 February 2013
FYI: James Love (james.love@keionline.org, +1.202.361.3040), Krista Cox (krista.cox@keionline.org, +1.202.332.2670) or Thiru Balasubramaniam (thiru@keionline.org).
The 27 February 2013 agreements between the Medicines Patent Pool (MPP) and ViiV Healthcare, a joint venture of GlaxoSmithKline, Pfizer, and Shionogi will expand access to affordable pediatric formulas for HIV/AIDS.
On 26 February 2013, one week before the WTO TRIPS Council (5-6 March 2013) meets to consider the LDC Group’s request (IP/C/W/583) for an extension of the transitional period under Article 66.1 of the TRIPS Agreement, UNDP and Continue Reading
On January 8, 2013, the US Department of Justice (DOJ) and the U.S. Patent and Trademark Office (PTO) issued a joint statement on “remedies for standards-essential patents subject to voluntary F/RAND commitments. (Copy of statement here). Continue Reading
The following statement was delivered at the 19th session of the WIPO Standing Committee on the Law Of Patents (SCP) after presentations by the secretariats of WIPO, WHO and WTO on the trilateral report.
26 February 2013
The following WTO airgram WTO/AIR/4075/REV.1 (22 February 2013) contains the agenda for the upcoming WTO Council for TRIPS meeting to be held in Geneva from Tuesday, 5 March 2013 to Wednesday, 6 March 2013. The March 2013 session of the TRIPS Council will discuss the LDC Group’s request (IP/C/W/583) for an extension of the transitional period under Article 66.1 of the TRIPS Agreement under agenda item 11. Continue Reading
On 17 October 2012, the State Intellectual Property Office of China submitted the following comments to the Electronic Forum of WIPO’s Standing Committee on the Law of Patents (SCP) in relation to the future work of the Committee. The written submission focused on: 1) Exceptions and Limitations to Patent Rights, 2. Quality of Patents and 3. Patents and Health. These points were encapsulated in China’s general intervention today.
[English translation by WIPO]
Continue ReadingWIPO patent committee to discuss patent quality (including opposition systems), L&Es and patents and health
The 19th session of the WIPO Standing Committee on the Law of Patents (SCP) meets in Geneva from 25 February 2013 to 28 February 2013. The 18th session of the SCP ended on a contentions note as WIPO member states could not agree upon the future work of the Committee. In fact, SCP 19 was initially scheduled for November 2012 but was delayed till February 2013 as WIPO’s membership thought informal discussions were required to produce a successful outcome for the future work of the patent committee.
EU and US push WIPO negotiations against human rights, for restrictions on exceptions
WIPO is spending five days in a special session to work on the text for a treaty on copyright exceptions for persons who are blind or have other disabilities.
KEI has obtained a copy of the latest version as of Friday morning, which is attached below.
The first four days have been consumed with highly technical but important debates of the international rules for copyright exceptions. The US and the EU are demanding that all sorts of language be put into the treaty referring to a three step test to restrict the use of exceptions.
Comments on the the Bayer appeal of the compulsory license on Nexavar patents, February 17, 2013
These are KEI’s February 17, 2013 comments on the the Bayer appeal of the compulsory license on Nexavar patents.
Comments on the the Bayer appeal of the compulsory license on Nexavar patents.
February 17, 2013
The dispute is Bayer Corporation v Natco Pharma Limited, and is being heardbefore the Intellectual Property Appellate Board At Chennai (O.R.A. no. 35/PT/2012).
